Harbour BioMed Receives Chinese Regulatory Approval of IND Application to Begin Seamless Phase 2/3 Clinical Trial of HBM9161 in Graves’ Ophthalmopathy
CAMBRIDGE, Mass. & ROTTERDAM, The Netherlands & SUZHOU, China--(BUSINESS WIRE)--Harbour BioMed receives IND approval in China to begin seamless Phase 2/3 clinical trial of HBM9161 in Graves' ophthalmopathy.